Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants

PHASE4TerminatedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

January 31, 2009

Conditions
PrematurityRespiratory Distress SyndromePatent Ductus Arteriosus
Interventions
DRUG

Survanta (beractant)

beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)

DRUG

Curosurf (poractant)

poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)

Trial Locations (1)

02118

Boston Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dey LP

UNKNOWN

lead

Alan Fujii

OTHER